Trial Profile
Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs REC 2282 (Primary)
- Indications Acute myeloid leukaemia; Advanced breast cancer; Biliary cancer; Carcinoma; Chronic lymphocytic leukaemia; Hodgkin's disease; Leukaemia; Lymphoma; Mantle-cell lymphoma; Meningioma; Multiple myeloma; Neurilemmoma; Neurofibromatosis 2; Non-Hodgkin's lymphoma; Pancreatic cancer; Small cell lung cancer; Solid tumours; Testicular cancer; Urogenital cancer; Uveal melanoma
- Focus Adverse reactions; First in man
- 07 Oct 2021 Results (n=57) of Pop PK analysis assessing whether or not use of body size-normalized dosing could reduce observed pharmacokinetic variability using data from two clinical studies NCT01129193 and NCT01798901 published in the European Journal of Drug Metabolism and Pharmacokinetics
- 21 Mar 2020 Results (n=55) of NCT01129193 (the FIH) and NCT01798901 assessing pharmacokinetic analysis for evaluation of oral absorption models and body size descriptors as potential sources of inter-individual variability in REC- 2282 PK, presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 31 May 2018 Status changed from active, no longer recruiting to completed.